Mirae Asset believes in changing the future through investment
New Update
FDA Clears IND Application for Accent Therapeutics Lead Compound ATX-559. Learn more here.
Mirae Asset Financial Group:
As of June 30, 2024 – Mirae Asset Financial Group
Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments
It is the first and only U.S. affiliate of Mirae Asset dedicated to investment in Life Science
First Fund Stats:
A differentiated investment strategy rooted in drug development, clinical data, and market dynamics
We invest in companies prioritizing the delivery of safe and effective treatments, as fast as possible, to patients who need them most
